This report, complemented by data from previous cases, strongly suggests shared pathways between JAK2 activation and oncogenic events resulting in ALL, CML and probably additional lympho- and myeloproliferative disorders. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.